EP1237848A1 - Process for the preparation of 3-amino-3-cyclopropylpropanoate esters - Google Patents

Process for the preparation of 3-amino-3-cyclopropylpropanoate esters

Info

Publication number
EP1237848A1
EP1237848A1 EP00984283A EP00984283A EP1237848A1 EP 1237848 A1 EP1237848 A1 EP 1237848A1 EP 00984283 A EP00984283 A EP 00984283A EP 00984283 A EP00984283 A EP 00984283A EP 1237848 A1 EP1237848 A1 EP 1237848A1
Authority
EP
European Patent Office
Prior art keywords
formula
radical
alkyl
inert solvent
amino ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00984283A
Other languages
German (de)
French (fr)
Inventor
Daniel John Bayston
Jonathan Luke William Griffin
Mario Eugenio Cosimino Polywka
Ronald Michael Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastman Chemical Co
Original Assignee
Eastman Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastman Chemical Co filed Critical Eastman Chemical Co
Publication of EP1237848A1 publication Critical patent/EP1237848A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Definitions

  • This invention pertains to a process for preparing 3-amino-3-cyclo- propylpropanoate esters, i.e., esters of 3-amino-3-cyclopropylpropanoic acid ( ⁇ -cyclopropylalanine esters or ⁇ -CPA esters) including racemic and substantially enantiomerically pure (R) or (S)- ⁇ -CPA esters.
  • this invention pertains to a process for the preparation of ⁇ -CPA esters by a 3-step process wherein cyclopropanecarboxaldehyde (CPCA) is reacted with a phosphonate reagent to obtain an ⁇ , ⁇ -unsaturated ester which is reacted with an enantiomerically-enriched lithium amide to produce an arylalkyl-amino ester compound; and the arylalkyl residue is removed from the amino group by hydrogenolysis to give the ⁇ -CPA ester.
  • CPCA cyclopropanecarboxaldehyde
  • a phosphonate reagent to obtain an ⁇ , ⁇ -unsaturated ester which is reacted with an enantiomerically-enriched lithium amide to produce an arylalkyl-amino ester compound
  • the arylalkyl residue is removed from the amino group by hydrogenolysis to give the ⁇ -CPA ester.
  • the present invention also includes certain of
  • Patent Publication EP 0380312 A1 discloses a Patent Publication EP 0380312 A1.
  • R 1 is an alkyl radical, e.g., unsubstituted or substituted Ci - C 8 alkyl
  • R 2 and R 3 are independently selected from alkyl radicals
  • R 4 is an unsubstituted or substituted Ci - C 8 alkyl, carbocyclic aryl, or arylalkyl radical
  • R 5 is a carbocyclic aryl radical.
  • substantially enantiomerically pure refers to a compound possessing greater than 95% enantiomeric excess [ee] wherein enantiomeric excess is defined as the percent of one enantiomer minus the percent of the other enantiomer.
  • Another embodiment of the invention comprises process step (2) described above wherein a substantially enantiomerically pure lithium amide is used to produce a substantially enantiomerically pure amino ester having formula (IV).
  • the invention also includes the novel intermediate compounds produced and utilized in the above-described process, i.e., arylalkyl-amino esters (IV).
  • step (1) of the process a phosphonate having the formula
  • the alkyl radicals which R 1 , R 2 and R 3 represent may be unsubstituted or substituted, unbranched or branched, alkyl containing up to 8 carbon atoms.
  • unsubstituted alkyl include methyl, ethyl, propyl, butyl, isobutyl, tert-butyl, and 2-ethylhexyl.
  • substitutents which may be present on the substituted alkyl radicals include alkoxy, halogen such as chloro and bromo, alkylthio, and aryl, e.g., phenyl and substituted phenyl.
  • R 2 and R 3 preferably represent lower alkyl, e.g.
  • the base employed in step (1) may be an alkali metal or alkaline earth metal hydride, alkoxide or hydroxide, preferably sodium hydride.
  • the amount of base employed normally will give a base:CPCA mole ratio in the range of 0.5:1 to 10:1 , preferably 0.8:1 to 1.5:1.
  • the inert solvent employed in the first step preferably is an ether, e.g., a dialkyl ether containing 2 to 8 carbon atoms or tetrahydrofuran; a hydrocarbon, e.g., an aliphatic hydrocarbon containing 6 to 12 carbon atoms, a cycloaliphatic hydrocarbon containing 5 to 7 carbon atoms or an aromatic hydrocarbon containing 6 to 12 carbon atoms such as benzene and alkyl-substituted benzene, e.g., toluene, the xylenes and diisopropylbenzene; or a dipolr aprotic solvent such as an N,N-dialkylformamide, N,N-dialkylacetamide or N-alkylpyrrolidinone wherein the alkyl groups contain up to 4 carbon atoms.
  • the inert solvent preferably is an ether such as tetrahydrofuran
  • the first step may be carried out at a temperature in the range of -25°C up to the boiling point of the solvent, e.g., -25 to 50°C, preferably at a temperature of -10 to 20°C.
  • the mole ratio of CPCAphosphonate (I) normally will be 0.75:1 to1.25:1.
  • ⁇ , ⁇ -Unsaturated ester (II) produced in step (1) may be isolated, e.g., by standard extraction techniques known in the art and can be used directly in the next step.
  • the second step of the process comprises contacting ⁇ , ⁇ -unsat- urated ester (II) obtained from the first step with a lithium amide reactant having the formula:
  • R 4 represents an alkyl radical, a carbocyclic aryl radical or a an arylalkyl radical
  • R 5 is a carbocyclic aryl radical.
  • alkyl radicals which R 4 may represent are set forth above in the description of R 1 , R 2 and R 3 .
  • the carbocyclic aryl radical represented by R 4 and R 5 may be unsubstituted or substituted phenyl or naphthyl.
  • substituents which may be present on the phenyl and naphthyl radicals which R 4 and R 5 may represent include alkyl, e.g., Ci - C alkyl; alkoxy, e.g., Ci - C 4 alkoxy; halogen, e.g., chloro and bromo; nitro; hydroxy; and the like. Normally, the phenyl and naphthyl radicals will not be substituted by more than 2 of any such substituents.
  • R 4 preferably is a carbocyclic arylalkyl containing 7 to 10 carbon atoms, most preferably ⁇ - methylbenzyl, and R 5 preferably is phenyl.
  • the inert solvent employed in the second step may be selected from dialkyl ethers, cyclic ethers, hydrocarbons or a mixture thereof, e.g., the ether and hydrocarbon solvents described above for step (1).
  • the second step may be carried out at a temperature in the range of -80°C up to the boiling point of the solvent, preferably at a temperature of -70 to -40°C
  • the mole ratio of lithium amide (III): ⁇ , ⁇ -unsaturated ester (II) normally will be 0.75:1 to 1.5:1.
  • lithium amide (III) is a substantially enantiomerically pure compound, i.e., (R) or (S) lithium amide (III) wherein R 4 is arylalkyl
  • the process of step 2 is observed to proceed with >20:1 diastereoselectivity.
  • R 1 is tet ⁇ -butyl and R 4 is ⁇ -methylbenzyl
  • the addition of lithium amide reactant (III) to ⁇ , ⁇ -unsaturated ester (II) is observed to provide arylalkyl-amino ester (IV) in a 97:1 ratio of diastereomers.
  • the major diastereomer possesses either the (R,S) configuration [starting with the (R)-lithium amide] as shown in (IVa) or the (S,R) configuration [starting with the (S)-lithium amide] as shown in (IVb).
  • the minor diastereomer possesses the (R,R) or (S,S) configuration as shown in (IVc) and (IVd), respectively. This diastereoselectivity is advantageous for the preparation of substantially enantiomerically pure ⁇ -CPA esters.
  • the amino ester of formula (IV) from step (2) is subjected to a hydrogenolysis treatment to remove the arylalkyl and R 4 substituents, thereby producing the amino ester of formula (V).
  • the hydrogenolysis treatment of step (3) comprises contacting a solution of arylalkyl-aminoester (IV) in an inert solvent, preferably an alkanol, e.g., an alkanol containing 1 to 4 carbon atoms, water or an alkanol/water mixture, with hydrogen or a suitable hydrogen donor such as formic acid and a hydrogenation catalyst.
  • the hydrogenation catalyst may be selected from the metals of Group VIII and compounds thereof, e.g., nickel, palladium, platinum and the like.
  • the catalyst preferably comprises a supported palladium or platinum catalyst, e.g., catalysts comprising 2 to 20 weight percent, preferably 5 to 10 weight percent, palladium or platinum deposited on a catalyst support material.
  • Palladium and palladium hydroxide on carbon are particularly preferred hydrogenation catalysts.
  • the process described herein may be carried out at ambient pressures. However, pressures moderately below or above ambient pressure may be used in one or more of the steps of the process. For example, increased pressure may permit the use of higher reaction temperatures and/or may provide for enhanced contact of process materials, e.g., hydrogen contact in the hydrogenolysis of step (3).
  • hydrogen pressures for step (3) can be in the range of 1 to 100 atmospheres, preferably 1 to 30 atmospheres.
  • the amino ester of formula (V) may be hydrolyzed to the corresponding ⁇ -cyclopropylpropanoic acid ( ⁇ -CPA) having the formula
  • aqueous acid or base in a solvent comprising an ether, hydrocarbon, acetone, water or a mixture thereof.
  • suitable acids include mineral acids such as hydrohalic acids such as hydrochloric and hydrobromic acids; sulfuric acid; phosphoric acid; alkyl- and arylsulfonic acids such as methanesulfonic, benzenesulfonic and toluenesulfonic acids.
  • the acid preferably is hydrochloric acid.
  • the acid:amino ester (V) mole ratio is in the range of 1 :1 to 10:1.
  • the base may comprise an alkali metal or alkali earth metal hydroxide in a base:amino ester (V) mole ratio of 1 :1 to 10:1.
  • the hydrolysis may be carried out at a temperature of room temperature to the boiling point of the solvent, preferably at the boiling point of the solvent.
  • the reaction product produced by the hydrolysis normally is the acid addition salt of ⁇ -CPA (VI), e.g., the hydrochloride or sulfate of ⁇ -CPA (VI).
  • a second embodiment of the process of the present invention comprises process step (2) described above wherein a substantially enantiomerically pure lithium amide is used to produce a substantially enantiomerically pure amino ester having formula (IV).
  • This second embodiment comprises contacting an ⁇ , ⁇ -unsaturated ester having the formula:
  • amino ester (IV) comprises a mixture of diastereomers with the ratio of major to minor diastereomers of greater than 20:1 , preferably greater than 97:1.
  • the major diastereomer possesses either the (R,S) configuration [starting with the (R)-lithium amide] as shown in (IVa) or the (S,R) configuration [starting with the (S)-lithium amide] as shown in (IVb).
  • the minor diastereomer possesses the (R,R) configuration as shown in (IVc) and (S,S) configuration (IVd), respectively.
  • the HCI salt of the (S)-amino ester (3.0 g, 13.5 mmol) was dissolved in 4M HCI in dioxane (15 mL, 5 vol), and heated to 50°C with stirring for 16 hours. The dioxane was removed under reduced pressure, and acetone (30 mL, 10 vol) was added. The resulting milky slurry then was stirred vigorously for 15 minutes and then filtered. The filter cake was then washed with acetone (2 x 15 ml, 2 x 5 vol), and dried to give the HCI salt of (S)-D-CPA (2.0 g, 91% of theory) as a fine white powder.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Disclosed is a process for preparing 3-amino-3-cyclopropylpropanoate esters, i.e., β-cyclopropylalanine esters (β-CPA esters) including racemic and substantially enantiomerically-pure R or (S)-β-CPA esters. The process comprises reacting cyclopropanecarboxaldehyde (CPCA) with a phosphonate reagent to obtain an α,β-unsaturated ester which is reacted with an enantiomerically-enriched lithium amide to produce an arylalkyl-amino ester compound; and then removing the arylalkyl residue from the amino group by hydrogenolysis to give the β-CPA ester.

Description

PROCESS FOR THE PREPARATION OF 3-AMINO-3-CYCLOPROPYLPROPANOATE ESTERS
Introduction This invention pertains to a process for preparing 3-amino-3-cyclo- propylpropanoate esters, i.e., esters of 3-amino-3-cyclopropylpropanoic acid (β-cyclopropylalanine esters or β-CPA esters) including racemic and substantially enantiomerically pure (R) or (S)- β-CPA esters. More specifically, this invention pertains to a process for the preparation of β-CPA esters by a 3-step process wherein cyclopropanecarboxaldehyde (CPCA) is reacted with a phosphonate reagent to obtain an α,β-unsaturated ester which is reacted with an enantiomerically-enriched lithium amide to produce an arylalkyl-amino ester compound; and the arylalkyl residue is removed from the amino group by hydrogenolysis to give the β-CPA ester. The present invention also includes certain of the individual process steps and intermediate compounds. β-Amino acids are an important class of organic compounds and often are found in physiologically active compounds. See, for example, Suffness, Ed., Taxot® Science and Applications (CRC, Boca Raton, FL, 1995) and Plattner, in Annual reports in Medicinal Chemistry, J. A. Bristol,
Ed (Academic Press, San Diego, 1994), vol 29, pp. 113-22. Similarly, the cyclopropyl fragment also is found in pharmaceutical products. See, for example, British Patent Publication GB 1 ,136,214, U.S. Patent 3,433,791 , Published PCT Patent Application WO 9304047, Spanish Patent ES 539110, U.S. Patent 4,863,918, Czech Patent CZ 279821 and European
Patent Publication EP 0380312 A1.
Only one reference to an ester of a β-amino acid substrate of this type can be found in the literature and concerns the use of ethyl 3-amino-3- cyclopropylpropanoate in the synthesis of a platelet aggregation inhibitor, Published PCT Patent Application WO 9307867 A1 930429 (Application: WO 92-US8512). The racemic form of ethyl 3-amino-3-cyclopropyl- propanoate was prepared by the action of diazomethane and palladium acetate on the corresponding vinyl compound, the preparation of which is not trivial,
The use of enantiomerically enriched lithium amides in the preparation of β-amino acids has been reported in, for example, Tetrahedron, 50, 3975 (1994), Synlett, 461 (1993) and Tetrahedron: Asymmetry, 2, 183 (1991). None of these published procedures employs a cyclopropyl- carbonyl substrate.
Brief Summary of the Invention
We have developed a process for the preparation of both racemic and substantially enantiomerically pure (R) or (S)-β-CPA esters beginning with CPCA. Our novel process comprises the steps of: (1) contacting CPCA with a phosphonate having the formula (I):
in the presence of a base and an inert solvent to obtain an α,β-unsaturated ester having the formula (II):
(2) contacting the α,β-unsaturated ester of formula (II) with a lithium amide of formula (III):
in the presence of an inert solvent to obtain an amino ester compound having the formula (IV):
and
(3) contacting the amino ester compound of formula (IV) with hydrogen in the presence of a hydrogenation catalyst and an inert solvent to obtain an amino ester of the formula (V):
wherein R1 is an alkyl radical, e.g., unsubstituted or substituted Ci - C8 alkyl; R2 and R3 are independently selected from alkyl radicals; R4 is an unsubstituted or substituted Ci - C8 alkyl, carbocyclic aryl, or arylalkyl radical; and R5 is a carbocyclic aryl radical. The use of substantially enantiomerically pure (R) or (S) lithium amide (III) gives the corresponding substantially enantiomerically pure β-CPA ester whereas the use of racemic or achiral lithium amide (III) gives racemic β-CPA. As used herein, "substantially enantiomerically pure" refers to a compound possessing greater than 95% enantiomeric excess [ee] wherein enantiomeric excess is defined as the percent of one enantiomer minus the percent of the other enantiomer. Another embodiment of the invention comprises process step (2) described above wherein a substantially enantiomerically pure lithium amide is used to produce a substantially enantiomerically pure amino ester having formula (IV). The invention also includes the novel intermediate compounds produced and utilized in the above-described process, i.e., arylalkyl-amino esters (IV). In step (1) of the process, a phosphonate having the formula
is reacted with CPCA in the presence of a base in an inert solvent to produce an α,β-unsaturated ester having the formula
The alkyl radicals which R1, R2 and R3 represent may be unsubstituted or substituted, unbranched or branched, alkyl containing up to 8 carbon atoms. Examples of unsubstituted alkyl include methyl, ethyl, propyl, butyl, isobutyl, tert-butyl, and 2-ethylhexyl. Examples of the substitutents which may be present on the substituted alkyl radicals include alkoxy, halogen such as chloro and bromo, alkylthio, and aryl, e.g., phenyl and substituted phenyl. R2 and R3 preferably represent lower alkyl, e.g. alkyl of up to 4 carbon atoms. The base employed in step (1) may be an alkali metal or alkaline earth metal hydride, alkoxide or hydroxide, preferably sodium hydride. The amount of base employed normally will give a base:CPCA mole ratio in the range of 0.5:1 to 10:1 , preferably 0.8:1 to 1.5:1. The inert solvent employed in the first step preferably is an ether, e.g., a dialkyl ether containing 2 to 8 carbon atoms or tetrahydrofuran; a hydrocarbon, e.g., an aliphatic hydrocarbon containing 6 to 12 carbon atoms, a cycloaliphatic hydrocarbon containing 5 to 7 carbon atoms or an aromatic hydrocarbon containing 6 to 12 carbon atoms such as benzene and alkyl-substituted benzene, e.g., toluene, the xylenes and diisopropylbenzene; or a dipolr aprotic solvent such as an N,N-dialkylformamide, N,N-dialkylacetamide or N-alkylpyrrolidinone wherein the alkyl groups contain up to 4 carbon atoms. The inert solvent preferably is an ether such as tetrahydrofuran
The first step may be carried out at a temperature in the range of -25°C up to the boiling point of the solvent, e.g., -25 to 50°C, preferably at a temperature of -10 to 20°C. The mole ratio of CPCAphosphonate (I) normally will be 0.75:1 to1.25:1. α,β-Unsaturated ester (II) produced in step (1) may be isolated, e.g., by standard extraction techniques known in the art and can be used directly in the next step.
The second step of the process comprises contacting α,β-unsat- urated ester (II) obtained from the first step with a lithium amide reactant having the formula:
in the presence of an inert solvent to obtain an amino ester compound having the formula: in the presence of an inert solvent, such as an ether, hydrocarbon or mixture thereof wherein R4 represents an alkyl radical, a carbocyclic aryl radical or a an arylalkyl radical; and R5 is a carbocyclic aryl radical. Examples of the alkyl radicals which R4 may represent are set forth above in the description of R1, R2 and R3. The carbocyclic aryl radical represented by R4 and R5 may be unsubstituted or substituted phenyl or naphthyl. Examples of the substituents which may be present on the phenyl and naphthyl radicals which R4 and R5 may represent include alkyl, e.g., Ci - C alkyl; alkoxy, e.g., Ci - C4 alkoxy; halogen, e.g., chloro and bromo; nitro; hydroxy; and the like. Normally, the phenyl and naphthyl radicals will not be substituted by more than 2 of any such substituents. R4 preferably is a carbocyclic arylalkyl containing 7 to 10 carbon atoms, most preferably α- methylbenzyl, and R5 preferably is phenyl. The inert solvent employed in the second step may be selected from dialkyl ethers, cyclic ethers, hydrocarbons or a mixture thereof, e.g., the ether and hydrocarbon solvents described above for step (1). The second step may be carried out at a temperature in the range of -80°C up to the boiling point of the solvent, preferably at a temperature of -70 to -40°C The mole ratio of lithium amide (III): α,β-unsaturated ester (II) normally will be 0.75:1 to 1.5:1.
When lithium amide (III) is a substantially enantiomerically pure compound, i.e., (R) or (S) lithium amide (III) wherein R4 is arylalkyl, the process of step 2 is observed to proceed with >20:1 diastereoselectivity. For example, when R1 is tetτ-butyl and R4 is α-methylbenzyl, the addition of lithium amide reactant (III) to α,β-unsaturated ester (II) is observed to provide arylalkyl-amino ester (IV) in a 97:1 ratio of diastereomers. The major diastereomer possesses either the (R,S) configuration [starting with the (R)-lithium amide] as shown in (IVa) or the (S,R) configuration [starting with the (S)-lithium amide] as shown in (IVb). The minor diastereomer possesses the (R,R) or (S,S) configuration as shown in (IVc) and (IVd), respectively. This diastereoselectivity is advantageous for the preparation of substantially enantiomerically pure β-CPA esters.
(IVa) (IVb)
In the third step of our novel process, the amino ester of formula (IV) from step (2) is subjected to a hydrogenolysis treatment to remove the arylalkyl and R4 substituents, thereby producing the amino ester of formula (V). The hydrogenolysis treatment of step (3) comprises contacting a solution of arylalkyl-aminoester (IV) in an inert solvent, preferably an alkanol, e.g., an alkanol containing 1 to 4 carbon atoms, water or an alkanol/water mixture, with hydrogen or a suitable hydrogen donor such as formic acid and a hydrogenation catalyst. The hydrogenation catalyst may be selected from the metals of Group VIII and compounds thereof, e.g., nickel, palladium, platinum and the like. The catalyst preferably comprises a supported palladium or platinum catalyst, e.g., catalysts comprising 2 to 20 weight percent, preferably 5 to 10 weight percent, palladium or platinum deposited on a catalyst support material. Palladium and palladium hydroxide on carbon are particularly preferred hydrogenation catalysts.
The process described herein may be carried out at ambient pressures. However, pressures moderately below or above ambient pressure may be used in one or more of the steps of the process. For example, increased pressure may permit the use of higher reaction temperatures and/or may provide for enhanced contact of process materials, e.g., hydrogen contact in the hydrogenolysis of step (3). In particular, hydrogen pressures for step (3) can be in the range of 1 to 100 atmospheres, preferably 1 to 30 atmospheres. The amino ester of formula (V) may be hydrolyzed to the corresponding β-cyclopropylpropanoic acid (β-CPA) having the formula
by means of conventional hydrolysis procedures using an aqueous acid or base in a solvent comprising an ether, hydrocarbon, acetone, water or a mixture thereof. Examples of suitable acids include mineral acids such as hydrohalic acids such as hydrochloric and hydrobromic acids; sulfuric acid; phosphoric acid; alkyl- and arylsulfonic acids such as methanesulfonic, benzenesulfonic and toluenesulfonic acids. The acid preferably is hydrochloric acid. The acid:amino ester (V) mole ratio is in the range of 1 :1 to 10:1. The base may comprise an alkali metal or alkali earth metal hydroxide in a base:amino ester (V) mole ratio of 1 :1 to 10:1. The hydrolysis may be carried out at a temperature of room temperature to the boiling point of the solvent, preferably at the boiling point of the solvent. The reaction product produced by the hydrolysis normally is the acid addition salt of β-CPA (VI), e.g., the hydrochloride or sulfate of β-CPA (VI).
A second embodiment of the process of the present invention comprises process step (2) described above wherein a substantially enantiomerically pure lithium amide is used to produce a substantially enantiomerically pure amino ester having formula (IV). This second embodiment comprises contacting an α,β-unsaturated ester having the formula:
with a substantially enantiomerically pure lithium amide having the formula:
in the presence of an inert solvent to obtain the amino ester having the formula:
wherein R1, R4 and R5 are defined above and amino ester (IV) comprises a mixture of diastereomers with the ratio of major to minor diastereomers of greater than 20:1 , preferably greater than 97:1. The major diastereomer possesses either the (R,S) configuration [starting with the (R)-lithium amide] as shown in (IVa) or the (S,R) configuration [starting with the (S)-lithium amide] as shown in (IVb). The minor diastereomer possesses the (R,R) configuration as shown in (IVc) and (S,S) configuration (IVd), respectively.
The operation of the process and preparation of the novel compounds provided by our invention are further illustrated by the following examples. The identities of the products obtained were confirmed by nuclear magnetic resonance spectrometry, mass spectrometry and infra-red spectrometry. The percentages specified in the examples are by weight unless otherwise specified.
EXAMPLE 1
To NaH (42.8 g of a 60% dispersion in oil, 1.07 mol) was added THF (500 mL, 10 vol) with stirring. The reaction mixture was then cooled to 0°C, and a solution of diethyl te/f-butyloxycarbonylmethylphosphonate (180.0 g, 0.7 mol) in THF (350 mL, 7 vol) was added over 0.5 hours such that the temperature was maintained below 10°O This mixture then was allowed to stir for 15 minutes and a solution of CPCA (50.0 g, 0.7 mol) dissolved in tetrahydrofuran (THF) (150 mL, 3 vol) was added over 45 minutes. During the addition of the CPCA solution the temperature of the reaction mixture never exceeded 10°C The resulting solution then was allowed to warm to room temperature, and was stirred a further 0.5 hours. Water (500 mL, 10 vol) was added whereupon the reaction mixture became clear. The THF then was removed in vacuo after which the oily residue was transferred to a separating funnel. Tertiary butyl methyl ether (TBME, 400 mL, 8 vol) was added, and the two-phase system was mixed thoroughly. The organic layer was separated and the aqueous phase was again washed with TBME (400 mL, 8 vol). The combined organic extracts were washed with brine (600 mL, 6 vol), dried over magnesium sulfate and filtered after which the solvent was removed under reduced pressure. The resulting oil then was distilled under reduced pressure (2 mbar) at 80°C (still head temperature = 66 - 68°C) through a vigreux column to give the desired α,β-unsaturated ester (91.62 g, 76% of theory) as a colourless oil.
A stirring solution of jb/s-[(R,RJ-α-methylbenzyl]amine (1.61g, 7.14 mmol) in dimethoxyethane (DME, 7.5 mL, 7.5 vol) was cooled to 0°C To this solution n-BuLi (4.61 ml of a 1.6 M solution in hexanes, 7.14 mmol) was added, and stirred for 30 minutes maintaining the temperature at < 5°O The resulting heterogeneous reaction mixture then was cooled to -63°C, and a solution of the α,β-unsaturated ester from the procedure of the preceding paragraph (1.00 g, 5.95 mmol) in DME (7.5 mL, 7.5 vol) was added over 30 minutes, ensuring that the temperature of the reaction mixture did not exceed -60°C After 4 hours at this temperature the deep purple reaction mixture was warmed to -40°C, and quenched with saturated ammonium chloride solution (2 mL, 2 vol). From the now yellow solution, the DME was removed under reduced pressure to give a yellow oil to which water (10 mL, 10 vol) , and TBME (10 mL, 10 vol) was added. From a separating funnel the aqueous phase was removed, and the resulting organic layer was washed with concentrated citric acid (2 x 10 mL, 2 x 10 vol), followed by saturated sodium bicarbonate solution (10 mL, 10 vol), and finally brine (10 mL, 10 vol). The resulting organic phase then was dried (magnesium sulfate), and the TBME was removed under reduced pressure to give the desired crude Michael adduct ((Sj-configuration at the new chiral center, 1.89 g, 81% of theory) as a colourless oil.
Ethanol (70 mL, 3.5 vol) was added to 5 weight percent palladium on carbon (3.0 g, 15% w/w) under nitrogen with stirring. To this ethanol/catalyst mixture was added the crude N-protected amino ester prepared according to the preceding paragraph (20.0 g, 50.9 mmol) in ethanol (80 mL, 4 vol), followed by the addition of formic acid (8.0 g, 175.0 mmol). The resulting mixture was heated to reflux for 23 hours. After cooling to room temperature, the catalyst was removed by filtration. The filtrate was concentrated in vacuo to give a colourless oil which was dissolved in TBME (100 mL, 5 vol). This solution was cooled to 0°C and 1M HCI in ether (50.9 mL, 50.9 mmol) was added drop-wise. The resulting slurry was allowed to stir for 5 minutes and then the white precipitate was filtered off, and washed with TBME (2 x 50 m, 2 x 2.5 vol). The white solid then was dried giving the HCI salt of (S)-fett-butyl 3-amino-3-cyclopropyl- propanoate (7.9 g, 70% of theory, >98% ee by GC).
The HCI salt of the (S)-amino ester (3.0 g, 13.5 mmol) was dissolved in 4M HCI in dioxane (15 mL, 5 vol), and heated to 50°C with stirring for 16 hours. The dioxane was removed under reduced pressure, and acetone (30 mL, 10 vol) was added. The resulting milky slurry then was stirred vigorously for 15 minutes and then filtered. The filter cake was then washed with acetone (2 x 15 ml, 2 x 5 vol), and dried to give the HCI salt of (S)-D-CPA (2.0 g, 91% of theory) as a fine white powder.

Claims

CLAIMS We claim:
1. Process which comprises the steps of:
(1) contacting cyclopropanecarboxaldehyde (CPCA) with a phosphonate having the formula:
in the presence of a base and an inert solvent to obtain an α,β-unsaturated ester having the formula:
(2) contacting the α,β-unsaturated ester of formula (II) with a lithium amide of formula (III):
in the presence of an inert solvent to obtain an amino ester compound having the formula: and
(3) contacting the amino ester compound of formula (IV) with hydrogen or hydrogen donor in the presence of a hydrogenation catalyst and an inert solvent to obtain an amino ester of the formula (V):
wherein R1 is an alkyl radical; R2 and R3 are independently selected from alkyl radicals; R4 is an alkyl radical, a carbocyclic aryl radical, or an arylalkyl radical; and R5 is a carbocyclic aryl radical.
2. Process according to Claim 1 wherein R1, R2 and R3 are independently selected from Ci - Cs alkyl.
3. Process according to Claim 2 wherein step (1) is carried out at a temperature of -25 to 50°C in the presence of a base selected from alkali metal and alkaline earth metal hydrides and alkoxides; step (2) is carried out at a temperature of -70 to -40°C; and step (3) comprises contacting the amino ester compound of formula (IV) with hydrogen or formic acid in the presence of a hydrogenation catalyst selected from nickel, palladium or platinum hydrogenation catalysts and an inert solvent selected from an alkanol containing 1 to 4 carbon atoms, water or a mixture thereof.
4. Process according to Claim 3 wherein R4 is a carbocyclic arylalkyl radical containing 7 to 10 carbon atoms and R5 is phenyl.
5. Process which comprises the steps of:
(1) contacting cyclopropanecarboxaldehyde (CPCA) with a phosphonate having the formula:
at a temperature of -10 to 20°C in the presence of sodium hydride and an inert solvent selected from ethers, hydrocarbons or mixture thereof to obtain an α,β-unsaturated ester having the formula:
(2) contacting the α,β-unsaturated ester of formula (II) with a lithium amide having the formula:
at a temperature of -70 to -40°C in the presence of an inert solvent selected from ethers, hydrocarbons or mixture thereof to obtain an amino ester compound having the formula: and
(3) contacting the amino ester compound of formula (IV) with hydrogen or formic acid in the presence of a hydrogenation catalyst comprising 2 to 20 weight percent palladium or platinum deposited on a catalyst support material and an inert solvent selected from an alkanol containing 1 to 4 carbon atoms, water or a mixture thereof, to obtain an amino ester of the formula (V):
wherein R1, R2 and R3 are independently selected from Ci - C8 alkyl; R4 is α-methylbenzyl, and R5 is phenyl.
6. A compound having the formula
wherein R1 is an alkyl radical; R4 is an alkyl radical, a carbocyclic aryl radical, or an arylalkyl radical; and R5 is a carbocyclic aryl radical.
7. A compound according to Claim 6 wherein R1 is Ci - C8 alkyl; R4 is a carbocyclic arylalkyl radical containing 7 to 10 carbon atoms; and R5 is phenyl.
8. A compound according to Claim 7 wherein R is α-methylbenzyl.
9. Process which comprises contacting an ,β-unsatu rated ester having the formula:
with a substantially enantiomerically pure lithium amide having the formula:
in the presence of an inert solvent to obtain the amino ester having the formula:
wherein R1 is an alkyl radical; R4 is an alkyl radical, a carbocyclic aryl radical, or an arylalkyl radical; and R5 is a carbocyclic aryl radical; and amino ester (IV) comprises a mixture of diastereomers with the ratio of major to minor diastereomers of greater than 20:1.
10. Process according to Claim 9 carried out at a temperature of -70 to -40°C wherein R1 is Ci - C8 alkyl; R4 is a carbocyclic arylalkyl radical containing 7 to 10 carbon atoms; R5 is phenyl; and amino ester (IV) comprises a mixture of diastereomers with the ratio of major to minor diastereomers of greater than 97:1.
EP00984283A 1999-12-15 2000-12-13 Process for the preparation of 3-amino-3-cyclopropylpropanoate esters Withdrawn EP1237848A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46518799A 1999-12-15 1999-12-15
US465187 1999-12-15
PCT/US2000/033732 WO2001044169A1 (en) 1999-12-15 2000-12-13 Process for the preparation of 3-amino-3-cyclopropylpropanoate esters

Publications (1)

Publication Number Publication Date
EP1237848A1 true EP1237848A1 (en) 2002-09-11

Family

ID=23846811

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00984283A Withdrawn EP1237848A1 (en) 1999-12-15 2000-12-13 Process for the preparation of 3-amino-3-cyclopropylpropanoate esters

Country Status (2)

Country Link
EP (1) EP1237848A1 (en)
WO (1) WO2001044169A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239113A (en) * 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0144169A1 *

Also Published As

Publication number Publication date
WO2001044169A1 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
RU2753548C1 (en) Method for producing nicotine
CA2466779C (en) Methods for preparing o-desmethylvenlafaxine
KR20240006498A (en) Synthesis of omecamtive mecarville
EP0529842A2 (en) Production of fluoxetine and new intermediates
AU744895B2 (en) Process to make chiral compounds
KR20060126965A (en) Process for preparing O-carbamoyl compound in the presence of active amine group
US20040106818A1 (en) Process for the preparation of cyclohexanol derivatives
KR100712003B1 (en) Method for preparing penserine and its analogs
KR20030000217A (en) Process for the preparation of cyclohexanol derivatives
WO2001044169A1 (en) Process for the preparation of 3-amino-3-cyclopropylpropanoate esters
EP1213279A1 (en) Venlafaxine production process
JP2002518364A (en) Symmetric and asymmetric disubstitution of carboxamides using organic titanates and Grignard reagents
US6191306B1 (en) Process for the preparation of cyclopropylglycine
JP4195231B2 (en) Optically active secondary phosphine borane derivative and method for producing the same
CN101218218B (en) Novel Pyrocatechol Derivatives
JP2001500151A (en) New intermediates for the production of verapamil derivatives
JPH0637449B2 (en) Process for producing optically active atenolol and its intermediates
WO2008037503A2 (en) Process for making aminoalkylphenyl carbamates and intermediates therefor
WO2007024113A1 (en) Process for the preparation of chiral 3-hydroxy pyrrolidine compound and derivatives thereof having high optical purity
EP0873293B1 (en) Improved process for the preparation of alkyl or aryl aldehyde intermediates
EP1237846B1 (en) Preparation of 3-amino-3-cyclopropylpropanoate esters
JP2002518365A (en) Catalytic symmetric disubstitution of carboxamides using Grignard reagents
KR100390777B1 (en) A process for preparing pyridone derivative
JP4348126B2 (en) Process for producing optically active amino alcohols
KR100297802B1 (en) Method for preparing 2- (3-trifluoromethyl) anilinonicotinic acid 2- (N-morpholine) ethyl.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020529

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

17Q First examination report despatched

Effective date: 20031128

RBV Designated contracting states (corrected)

Designated state(s): CH DE FR GB LI

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041127